If you have been reading about heptapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
| Property | Value | Notes |
|---|---|---|
| Primary research models | Rodent studies | Largest share of published data |
| Reported markers | BDNF and NGF expression | Measured mainly in animal tissue |
| Common administration | Intranasal | Matches the registered formulation |
| Blood residence time | Minutes | Rapid enzymatic degradation |
| Evidence quality | Small trials, limited replication | Noted repeatedly in reviews |
Verification of a supplied batch generally combines a certificate of analysis with independent testing, because certificates are self-reported documents. A typical package includes a chromatographic trace, a mass spectrum, and a stated water or counter-ion content. Batch-to-batch consistency matters more than a single purity figure when results are compared across experiments. No single mandatory standard governs research-grade peptide release, so laboratories are expected to define their own acceptance criteria. Residual trifluoroacetate from purification is a frequently overlooked counter-ion.
Lyophilized material is chemically stable for extended periods when kept dry, cold, and protected from light. The powder is hygroscopic, so vials should be warmed to room temperature before opening to reduce condensation on the contents. Once dissolved, the peptide is far less stable because peptide bonds are susceptible to hydrolysis and the methionine residue can oxidize. Solutions are typically aliquoted and held at 2-8 °C for short intervals or frozen for longer ones, and repeated freeze-thaw cycles should be avoided.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.
Identity and purity are confirmed with reversed-phase high-performance liquid chromatography, typically monitored at 214 nanometres where the peptide bond absorbs. Mass spectrometry, either electrospray or MALDI-TOF, verifies molecular mass against the theoretical value and detects truncation or adduct formation. Amino acid analysis and peptide mapping provide additional confirmation when required. The most frequently reported impurities are deletion sequences from incomplete coupling, methionine sulfoxide from oxidation, and dimeric species formed through non-covalent aggregation. Impurity profiles depend strongly on the synthesis and purification route chosen by the producer.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
In what some have called the First Cold War, from Britain's intervention in the Russian Civil War in 1918 to its uneasy alliance with the Soviet Union against the Axis powers in 1941, British distrust of the revolutionary and regicidal Bolsheviks resulted in domestic, foreign, and colonial policies aimed at resisting the spread of communism. This conflict after 1945 took on new battlefields, new weapons, new players, and a greater intensity, but it was still fundamentally a conflict against Soviet imperialism (real and imagined). The idea of long-term continuity is a minority scholarly view that has been challenged. Frank Ninkovich writes:
Azurin's other domains may also exhibit strong anticancer activity by binding to cell surface receptor tyrosine kinases such as EphB2 receptors, which induce angiogenesis in cancer cells. This is another mechanism by which azurin has been proposed to exhibit its therapeutic effects.
== Further reading == Laurence J. Alison, Marie Eyre: Killer in the Shadows: The Monstrous Crimes of Robert Napper. Pennant Books 2009, ISBN 978-1-906015-49-7. Kevin Brewer: Psychology and Crime. Heinemann Educational Publishers 2000, ISBN 978-0-435-80653-8. Paul Britton: The Jigsaw Man. Corgi Books 1998, ISBN 978-0-552-14493-3. Colin Evans: A Question of Evidence: The Casebook of Great Forensic Controversies, from Napoleon to O.J. Wiley 2002, ISBN 978-0-471-44014-7. Mike Fielder: The Murder of Rachel Nickell. John Blake 2000, ISBN 978-1-85782-338-7. Alex Handscombe: Letting Go: A true story of murder, loss and survival by Rachel Nickell's son. Harper Element 2017, ISBN 978-0008144296. André Hanscombe: The Last Thursday in July. Century 1996 / Arrow 1997, ISBN 978-0-09-917512-4. David Kessler: Rachel Nickell, House of Solomon Ltd, 2001, ISBN 978-1-904037-03-3. Keith Pedder: The Rachel Files, John Blake 2002, ISBN 978-1-904034-30-8. Keith Pedder: Murder on the Common: The Secret Story of the Murder That Shocked a Nation. John Blake 2003, ISBN 978-1-84454-057-0. Colin Stagg, David Kessler: Who Really Killed Rachel? Greenzone Publishing 1999, ISBN 978-0-9582027-2-5. Colin Stagg, David Kessler: The Lizzie James Conspiracy. House of Solomon 2001, ISBN 978-1-904037-00-2. Colin Stagg, Ted Hynds: Pariah: Colin Stagg. Pennant Publishing 2007, ISBN 978-1-906015-10-7. Brent E. Turvey: Criminal Profiling: An Introduction to Behavioral Evidence Analysis Academic Press 2002, ISBN 978-0-12-705041-6.
=== Anterograde neuronal transport === Molecules synthesized in the cell bodies of neurons must be conveyed outward to the distal synapses. This is accomplished via fast anterograde transport. It has been found that APP can mediate interaction between cargo and kinesin and thus facilitate this transport. Specifically, a short peptide 15-amino-acid sequence from the cytoplasmic carboxy-terminus is necessary for interaction with the motor protein. Additionally, it has been shown that the interaction between APP and kinesin is specific to the peptide sequence of APP. In a recent experiment involving transport of peptide-conjugated colored beads, controls were conjugated to a single amino acid, glycine, such that they display the same terminal carboxylic acid group as APP without the intervening 15-amino-acid sequence mentioned above. The control beads were not motile, which demonstrated that the terminal COOH moiety of peptides is not sufficient to mediate transport.
=== Operation Edzell === An undercover policewoman from the Metropolitan Police Special Operations Group (SO10) contacted Stagg, posing as a friend of a woman with whom he used to be in contact via a lonely hearts' column. Over five months, she attempted to obtain information from him by feigning a romantic interest, meeting him, speaking to him on the telephone and exchanging letters containing sexual fantasies. During a meeting in Hyde Park, they spoke about the Nickell homicide; he later said that he had only played along with the topic because he wanted to pursue the romance. Profiler Paul Britton later said that he disagreed with use of the fantasy-filled letters and knew nothing of them until after they had been sent. The undercover officer won Stagg's confidence and drew out fantasies from him that psychologist Paul Britton interpreted as "violent", but he did not admit to the killing. Police released a taped conversation between the police officer and him, in which she claimed to enjoy hurting people, to which he mumbled, "Please explain, as I live a quiet life. If I have disappointed you, please don't dump me. Nothing like this has happened to me before". When she went on to say, "If only you had done the Wimbledon Common murder, if only you had killed her, it would be all right", he replied, "I'm terribly sorry, but I haven't". Stagg was nevertheless arrested and charged on the basis of claims that he had described aspects of the murder scene that only the killer would have known.
Sources: en.wikipedia.org
Anti-Müllerian hormone (AMH), also known as Müllerian-inhibiting factor (MIF), is a protein that in humans is encoded by the AMH gene. AMH is a glycoprotein hormone that belongs to the transforming growth factor beta (TGF-β) superfamily, which also includes inhibin and activin. These hormones play important roles in cell growth and development, sex differentiation in males, and the formation of ovarian follicles. In humans, the AMH gene is located on chromosome 19p13.3, while its receptor is encoded by the AMHR2 gene on chromosome 12. In male embryos, AMH is switched on by the SOX9 gene in Sertoli cells of the developing testes. AMH acts to block the development of the Müllerian ducts (also called paramesonephric ducts), which would otherwise form the uterus, fallopian tubes, and upper part of the vagina. This allows male reproductive organs to develop. The production of AMH during this specific window of fetal development is tightly regulated by other factors, including the nuclear receptor SF-1, GATA transcription factors, the sex-determining gene DAX1, and follicle-stimulating hormone (FSH). Mutations in the AMH gene or its receptor (type II AMH receptor) can result in the persistence of Müllerian duct structures in otherwise normally developed males. In females, AMH is produced by granulosa cells in developing ovarian follicles, especially in the early (preantral and small antral) stages. AMH is present in the ovaries until menopause.
Ropinirole is metabolized primarily by cytochrome P450 CYP1A2 to form two metabolites; SK&F-104557 (N-Despropyl Ropinirole) and SK&F-89124, both of which are renally excreted, and at doses higher than clinical, is also metabolized by CYP3A4. At doses greater than 24 mg, CYP2D6 may be inhibited, although this has been tested only in vitro. 7-Hydroxyropinirole (SK&F-89124), a major metabolite of ropinirole in rats but minor metabolite in humans (<5% of dose), is a highly potent dopamine receptor agonist with antiparkinsonian activity similarly to ropinirole. It has been reported to be 30-fold more potent than ropinirole as a dopamine D2 receptor agonist in vitro. However, ropinirole and 7-hydroxyropinirole were equipotent in terms of antiparkinsonian activity in rodents in vivo. 7-Hydroxyropinirole is said to be the only metabolite of ropinirole known to possess significant dopaminergic activity in vivo, although other ropinirole metabolites have also been found to have dopaminergic activity.
August 5: The Partial Test Ban Treaty is signed by the US, UK and USSR, prohibiting the testing of nuclear weapons anywhere except underground. September 16: Malaysia was formed, with Tunku Abdul Rahman as its first prime minister. This was considered to have violated the Manila Accord because Malaysia was formed before the Sabah and Sarawak self-determination election results were reported. September 25: A border war was fought between Morocco and Algeria. October 14: The Aden Emergency begins against British rule. November 2: South Vietnamese President Ngo Dinh Diem is assassinated in a coup supported by the CIA. November 22: John F. Kennedy is shot and killed in Dallas. There has been some speculation over whether communist countries, or even the CIA, were involved in the assassination, but those theories remain controversial. Kennedy's vice-president Lyndon B. Johnson becomes President of the United States. December 12: Kenya becomes independent from the UK under Commonwealth status.
Rotary vane pump, the most common Diaphragm pump, zero oil contamination Liquid ring high resistance to dust Piston pump, fluctuating vacuum Scroll pump, highest speed dry pump Screw pump (10 Pa) Wankel pump External vane pump Roots blower, also called a booster pump, has highest pumping speeds but low compression ratio Multistage Roots pump that combine several stages providing high pumping speed with better compression ratio Toepler pump Lobe pump The base pressure of a rubber- and plastic-sealed piston pump system is typically 1 to 50 kPa, while a scroll pump might reach 10 Pa (when new) and a rotary vane oil pump with a clean and empty metallic chamber can easily achieve 0.1 Pa. A positive displacement vacuum pump moves the same volume of gas with each cycle, so its pumping speed is constant unless it is overcome by backstreaming.
===== MeSH D08.811.277.040 – acid anhydride hydrolases (EC 3.6) ===== MeSH D08.811.277.040.025 – adenosinetriphosphatase MeSH D08.811.277.040.025.095 – ca(2+) mg(2+)-atpase MeSH D08.811.277.040.025.125 – ca(2+)-transporting atpase MeSH D08.811.277.040.025.150 – dynein atpase MeSH D08.811.277.040.025.237 – muts dna mismatch-binding protein MeSH D08.811.277.040.025.281 – muts homolog 2 protein MeSH D08.811.277.040.025.303 – n-ethylmaleimide-sensitive proteins MeSH D08.811.277.040.025.325 – proton-translocating atpases MeSH D08.811.277.040.025.325.249 – bacterial proton-translocating atpases MeSH D08.811.277.040.025.325.500 – chloroplast proton-translocating atpases MeSH D08.811.277.040.025.325.625 – h(+)-k(+)-exchanging atpase MeSH D08.811.277.040.025.325.750 – mitochondrial proton-translocating atpases MeSH D08.811.277.040.025.325.875 – vacuolar proton-translocating atpases MeSH D08.811.277.040.025.450 – kinesin MeSH D08.811.277.040.025.525 – myosins MeSH D08.811.277.040.025.525.500 – myosin type i MeSH D08.811.277.040.025.525.750 – myosin type ii MeSH D08.811.277.040.025.525.750.124 – cardiac myosins MeSH D08.811.277.040.025.525.750.124.249 – atrial myosins MeSH D08.811.277.040.025.525.750.124.500 – ventricular myosins MeSH D08.811.277.040.025.525.750.374 – nonmuscle myosin type iia MeSH D08.811.277.040.025.525.750.500 – nonmuscle myosin type iib MeSH D08.811.277.040.025.525.750.750 – skeletal muscle myosins MeSH D08.811.277.040.025.525.750.875 – smooth muscle myosins MeSH D08.811.277.040.025.525.812 – myosin type iii MeSH D08.811.277.040.025.525.843 – myosin type iv MeSH D08.811.277.040.025.525.875 – myosin type v MeSH D08.811.277.040.025.600 – na(+)-k(+)-exchanging atpase MeSH D08.811.277.040.050 – apyrase MeSH D08.811.277.040.330 – gtp phosphohydrolases MeSH D08.811.277.040.330.200 – dynamins MeSH D08.811.277.040.330.200.100 – dynamin i MeSH D08.811.277.040.330.200.200 – dynamin ii MeSH D08.811.277.040.330.200.300 – dynamin iii MeSH D08.811.277.040.330.300 – gtp-binding proteins MeSH D08.811.277.040.330.300.100 – gtp phosphohydrolase-linked elongation factors MeSH D08.811.277.040.330.300.100.200 – peptide elongation factor g MeSH D08.811.277.040.330.300.100.700 – peptide elongation factor tu MeSH D08.811.277.040.330.300.100.800 – peptide elongation factor 1 MeSH D08.811.277.040.330.300.100.850 – peptide elongation factor 2 MeSH D08.811.277.040.330.300.200 – heterotrimeric gtp-binding proteins MeSH D08.811.277.040.330.300.200.100 – gtp-binding protein alpha subunits MeSH D08.811.277.040.330.300.200.100.100 – gtp-binding protein alpha subunits, g12-g13 MeSH D08.811.277.040.330.300.200.100.200 – gtp-binding protein alpha subunits, gi-go MeSH D08.811.277.040.330.300.200.100.200.500 – gtp-binding protein alpha subunit, gi2 MeSH D08.811.277.040.330.300.200.100.300 – gtp-binding protein alpha subunits, gq-g11 MeSH D08.811.277.040.330.300.200.100.400 – gtp-binding protein alpha subunits, gs MeSH D08.811.277.040.330.300.200.800 – transducin MeSH D08.811.277.040.330.300.400 – monomeric gtp-binding proteins MeSH D08.811.277.040.330.300.400.100 – adp-ribosylation factors MeSH D08.811.277.040.330.300.400.100.100 – ADP-ribosylation factor 1 MeSH D08.811.277.040.330.300.400.400 – rab gtp-binding proteins MeSH D08.811.277.040.330.300.400.400.025 – rab1 gtp-binding proteins MeSH D08.811.277.040.330.300.400.400.050 – rab2 gtp-binding protein MeSH D08.811.277.040.330.300.400.400.100 – rab3 gtp-binding proteins MeSH D08.811.277.040.330.300.400.400.100.500 – rab3a gtp-binding protein MeSH D08.811.277.040.330.300.400.400.150 – rab4 gtp-binding proteins MeSH D08.811.277.040.330.300.400.400.200 – rab5 gtp-binding proteins MeSH D08.811.277.040.330.300.400.450 – ral gtp-binding proteins MeSH D08.811.277.040.330.300.400.462 – ran gtp-binding protein MeSH D08.811.277.040.330.300.400.475 – rap gtp-binding proteins MeSH D08.811.277.040.330.300.400.475.100 – rap1 gtp-binding proteins MeSH D08.811.277.040.330.300.400.500 – ras proteins MeSH D08.811.277.040.330.300.400.500.300 – oncogene protein p21(ras) MeSH D08.811.277.040.330.300.400.500.600 – proto-oncogene proteins p21(ras) MeSH D08.811.277.040.330.300.400.700 – rho gtp-binding proteins MeSH D08.811.277.040.330.300.400.700.050 – cdc42 gtp-binding protein MeSH D08.811.277.040.330.300.400.700.060 – cdc42 gtp-binding protein, saccharomyces cerevisiae MeSH D08.811.277.040.330.300.400.700.100 – rac gtp-binding proteins MeSH D08.811.277.040.330.300.400.700.100.500 – rac1 gtp-binding protein MeSH D08.811.277.040.330.300.400.700.200 – rhoa gtp-binding protein MeSH D08.811.277.040.330.300.400.700.300 – rhob gtp-binding protein MeSH D08.811.277.040.465 – nucleoside-triphosphatase MeSH D08.811.277.040.600 – pyrophosphatases MeSH D08.811.277.040.600.399 – inorganic pyrophosphatase MeSH D08.811.277.040.600.800 – thiamine pyrophosphatase MeSH D08.811.277.040.850 – thiamin-triphosphatase
Sources: en.wikipedia.org
== Chemistry == 1S-LSD belongs to the lysergamide class of compounds, which are characterized by the ergoline structure derived from lysergic acid. The compound is closely related to LSD and 1P-LSD but differs by the addition of a trimethylsilyl group on the propionyl chain. The nitrogen atom in the polycyclic indole group of the ergoline structure is a common site for chemical modifications, as it is highly reactive and accessible for various reactions. These modifications often include alkylations, acylations, Mannich reactions, and Michael additions. Such alterations are frequently explored in the synthesis of new analogues to modify pharmacological properties or evade legal controls. The addition of the trimethylsilyl group in 1S-LSD represents a strategic modification designed to keep the substance outside the coverage of Germany's New Psychoactive Substances Act (NpSG). Despite these changes, 1S-LSD likely retains a pharmacological profile similar to that of LSD, acting primarily as a serotonergic hallucinogen.
An L-ribonucleic acid aptamer (L-RNA aptamer, trade name Spiegelmer) is an RNA-like molecule built from L-ribose units. It is an artificial oligonucleotide named for being a mirror image of natural oligonucleotides. L-RNA aptamers are a form of aptamers. Due to their L-nucleotides, they are highly resistant to degradation by nucleases. L-RNA aptamers are considered potential drugs and are currently being tested in clinical trials.
=== G-Man === The G-Man (voiced by Michael Shapiro) is a mysterious recurring character. He is known to display peculiar behavior, and capabilities beyond that of an ordinary human. His identity and motives remain almost entirely unexplained. He plays the role of an overseer and employer, both observing the player as the games progress and pulling strings to control the outcome of specific events throughout the Half-Life saga. The G-Man's constant appearances in the Half-Life games, as well as his revealing monologues with series protagonist Gordon Freeman, imply that he is of great importance and somewhat anchors the efforts of the player. His mysterious nature has made him an icon of the Half-Life series. During the development of Half-Life, after the designers discovered the usefulness of allied NPCs, the development team began to cast for characters who were "neither allies nor outright enemies, but existed mainly to create a sense of intrigue", which eventually led to the creation of the G-Man. According to Half-Life writer Marc Laidlaw, G-Man was inspired by the character Slowslop in Synergy's computer game Gadget: Invention, Travel, & Adventure (1993), which Laidlaw had adapted into a novel in 1996.
Soon after plants are water-stressed and the roots are deficient in water, a signal moves up to the leaves, causing the formation of ABA precursors there, which then move to the roots. The roots then release ABA, which is translocated to the foliage through the vascular system and modulates potassium and sodium uptake within the guard cells, which then lose turgidity, closing the stomata.
On the other hand, if the principal plane of the analyzer is along DOC then both the halves will be equally dark. Thus it is clear that if the analyzing Nicol is slightly disturbed from DOC then one half becomes brighter than the other. Hence by using the half shade device, one can measure the angle of rotation more accurately. Determination of specific rotation: In order to determine a specific rotation of an optically active substance (say, sugar), the polarimeter tube is first filled with pure water and the analyzer is adjusted for equal darkness (both the halves should be equally dark) point. The position of the analyzer is noted with the help of the scale. Now the polarimeter tube is filled with a sugar solution of known concentration and again the analyzer is adjusted in such a way that again the equally dark point is achieved. The position of the analyzer is again noted. The difference of the two readings will give the angle of rotation θ. Hence, a specific rotation S is determined as S = θ/LC, where L is the optical path length and C is concentration of the substance.
Sources: en.wikipedia.org
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.
The compound is registered as a medicine in Russia, so clinical work has concentrated there. Trials elsewhere are few and generally small. This geographic concentration is a recognized limitation in evidence reviews.
Some fraction may reach the central nervous system through olfactory pathways, and this is often cited as the rationale for the nasal route. The size of that fraction in humans is not well quantified. Blood concentrations after nasal dosing are low, which complicates measurement.
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.